Olson, Matthew R <br/><br/>
Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease.  [electronic resource] 

 -  Journal of immunology (Baltimore, Md. : 1950)  Mar 2009 
 - 3024-31 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1550-6606 
<br/><br/><label>Standard No.: </label>10.4049/jimmunol.0803585  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--administration & dosage<br/>Animals<br/>Autoimmune Diseases--genetics<br/>CD4-Positive T-Lymphocytes--immunology<br/>CD8-Positive T-Lymphocytes--immunology<br/>Cell Differentiation--genetics<br/>Epitopes, T-Lymphocyte--immunology<br/>Fas Ligand Protein--biosynthesis<br/>Humans<br/>Immunization, Secondary<br/>Immunologic Memory--genetics<br/>Lymphatic Diseases--genetics<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Mutant Strains<br/>Pulmonary Eosinophilia--genetics<br/>Respiratory Syncytial Virus Vaccines--administration & dosage<br/>Respiratory Syncytial Viruses--immunology<br/>Viral Envelope Proteins--administration & dosage